Galecto Biotech AB announced the appointment of Richard Marshall, MD, PhD, as chief medical officer. Dr Marshall joins Galecto with more than 15 years of experience across drug discovery, clinical development and business development in various positions at Glaxo Smithkline (GSK).    Most recently, he was Vice-President and Head of the Fibrosis & Lung Injury Discovery Performance Unit. During his tenure at GSK, Dr Marshall led the early clinical development for NucalaTM, anti-IL-5 mA...